Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Adicet Bio Inc ACET

Healthcare Biotechnology
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the... see more

Recent & Breaking News (NDAQ:ACET)

resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson's Disease and Provides Corporate Update

GlobeNewswire February 19, 2020

resTORbio to Present at Upcoming Investor Conferences

GlobeNewswire November 26, 2019

resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint

GlobeNewswire November 15, 2019

resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update

GlobeNewswire November 5, 2019

AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP

GlobeNewswire October 8, 2019

resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019

GlobeNewswire October 2, 2019

resTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 25, 2019

resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek(TM) 2019

GlobeNewswire September 23, 2019

resTORbio Reports Second Quarter 2019 Financial Results and Corporate Update

GlobeNewswire August 14, 2019

resTORbio to Present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019

GlobeNewswire August 7, 2019

resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness

GlobeNewswire July 23, 2019

resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in Patients 65 Years of Age and Older with Asthma

GlobeNewswire May 20, 2019

resTORbio Reports First Quarter 2019 Financial Results and Corporate Update

GlobeNewswire May 15, 2019

resTORbio Appoints Lloyd Klickstein, M.D., Ph.D., as Chief Scientific Officer

GlobeNewswire May 14, 2019

resTORbio to Present RTB101 Phase 2b Clinical Trial Data at American Thoracic Society 2019 International Conference

GlobeNewswire May 13, 2019

resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory Illness

GlobeNewswire May 9, 2019

resTORbio to Participate at Upcoming Investor Conferences in May

GlobeNewswire May 1, 2019

resTORbio Announces Initiation of Phase 1b/2a Trial of RTB101 in Parkinson’s Disease

GlobeNewswire April 2, 2019

resTORbio, Inc. Announces Closing Public Offering of Common Stock

GlobeNewswire March 22, 2019

resTORbio, Inc. Announces Pricing of Public Offering of Common Stock

GlobeNewswire March 19, 2019